Patents by Inventor Neil Bifulco
Neil Bifulco has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12709628Abstract: The present disclosure relates generally to STAT6 modulators and uses thereof, and more specifically to compounds, salts, and compositions thereof useful for treating conditions associated with STAT6.Type: GrantFiled: July 11, 2025Date of Patent: August 18, 2026Assignee: Recludix Pharma, Inc.Inventors: Howard Bregman, John Yeoman, Jennifer Downing, Samuel K. Reznik, Ernest Allen Sickmier, Giovanni Cianchetta, Rishi G. Vaswani, Neil Bifulco, Xia Tian, Andrew Tasker, Brian Hodous
-
Patent number: 12583856Abstract: Described herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof and solvates of any of the foregoing capable of inhibiting protein kinase A and/or its mutants, pharmaceutical compositions comprising at least one of the compounds, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, processes for making the compounds, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, and methods of using the same.Type: GrantFiled: February 1, 2022Date of Patent: March 24, 2026Assignee: Blueprint Medicines CorporationInventors: Neil Bifulco, Joseph L. Kim, Stefanie Sandra Schalm, Kevin J. Wilson, Michael Ross Palmer
-
Publication number: 20260015373Abstract: The present disclosure relates generally to STAT6 modulators and uses thereof, and more specifically to compounds, salts, and compositions thereof useful for treating conditions associated with STAT6.Type: ApplicationFiled: July 11, 2025Publication date: January 15, 2026Inventors: Howard BREGMAN, John YEOMAN, Jennifer DOWNING, Samuel K. REZNIK, Ernest Allen SICKMIER, Giovanni CIANCHETTA, Rishi G. VASWANI, Neil BIFULCO, Xia TIAN, Andrew TASKER, Brian HODOUS
-
Publication number: 20250215030Abstract: Provided are compounds of Formula (I) and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with STAT3 and/or STAT6.Type: ApplicationFiled: March 30, 2023Publication date: July 3, 2025Inventors: Neil Bifulco, Howard Bregman, Giovanni Cianchetta, Brian Hodous, Samuel K. Reznik, Yong Tang, Andrew Tasker, Rishi G. Vaswani, Ernest Allen Sickmier, John Yeoman, Xia Tian
-
Publication number: 20250215029Abstract: Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with STAT3 and/or STAT6.Type: ApplicationFiled: January 10, 2023Publication date: July 3, 2025Inventors: Howard Bregman, Neil Bifulco, Giovanni Cianchetta, Brian Hodous, Samuel K. Reznik, Ernest Allen Sickmier, Yong Tang, Andrew Tasker, Xia Tian, Rishi G. Vaswani, John Yeoman
-
Publication number: 20250179103Abstract: Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with STAT3 and/or STAT6, such as e.g. cancer and inflammatory conditions. Preferred compounds are 6-oxodecahydropyrrolo[1,2-a][1,5]diazocine and 6-oxodecahydro-4H-pyrrolo[2,1-d][1,5]thiazocine derivatives.Type: ApplicationFiled: February 27, 2023Publication date: June 5, 2025Inventors: Neil Bifulco, Howard Bregman, Giovanni Cianchetta, Brian Hodous, Samuel K. Reznik, Yong Tang, Andrew Tasker, Rishi G. Vaswani, Ernest Allen Sickmier, John Yeoman, Xia Tian
-
Publication number: 20240132490Abstract: Described herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof and solvates of any of the foregoing capable of inhibiting protein kinase A and/or its mutants, pharmaceutical compositions comprising at least one of the compounds, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, processes for making the compounds, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, and methods of using the same.Type: ApplicationFiled: February 1, 2022Publication date: April 25, 2024Applicant: Blueprint Medicines CorporationInventors: Neil Bifulco, Joseph L. Kim, Stefanie Sandra Schalm, Kevin J. Wilson, Michael Ross Palmer
-
Patent number: 11059827Abstract: This invention relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants.Type: GrantFiled: July 31, 2019Date of Patent: July 13, 2021Assignee: Blueprint Medicines CorporationInventors: Steven Mark Wenglowsky, Chandrasekhar V. Miduturu, Neil Bifulco, Joseph L. Kim
-
Publication number: 20190382410Abstract: This invention relates to inhibitors of NTRK that are active against wild-type NTRK and its resistant mutants.Type: ApplicationFiled: July 31, 2019Publication date: December 19, 2019Inventors: Steven Mark Wenglowsky, Chandrasekhar V. Miduturu, Neil Bifulco, Joseph L. Kim
-
Patent number: 9623014Abstract: The present invention is directed to compounds which are beta-lacatamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3 and R4 are described herein.Type: GrantFiled: February 29, 2016Date of Patent: April 18, 2017Assignee: Entasis Therapeutics LimitedInventors: Helen Mcguire, Shanta Bist, Neil Bifulco, Liang Zhao, Ye Wu, Hoan Huynh, Hui Xiong, Janelle Comita-Prevoir, Daemian Dussault, Bolin Geng, Brendan Chen, Thomas Francois Durand-Reville, Satenig Guler
-
Publication number: 20160175290Abstract: The present invention is directed to compounds which are beta-lacatamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3 and R4 are described herein.Type: ApplicationFiled: February 29, 2016Publication date: June 23, 2016Inventors: Helen Mcguire, Shanta Bist, Neil Bifulco, Liang Zhao, Ye Wu, Hoan Huynh, Hui Xiong, Janelle Comita-Prevoir, Daemian Dussault, Bolin Geng, Brendan Chen, Thomas Francois Durand-Reville, Satenig Guler
-
Patent number: 9309245Abstract: The present invention is directed to compounds which are beta-lacatamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3 and R4 are described herein.Type: GrantFiled: April 2, 2013Date of Patent: April 12, 2016Assignee: Entasis Therapeutics LimitedInventors: Helen McGuire, Shanta Bist, Neil Bifulco, Liang Zhao, Ye Wu, Hoan Huynh, Hui Xiong, Janelle Comita-Prevoir, Daemian Dussault, Bolin Geng, Brendan Chen, Thomas Durand-Reville, Satenig Guler
-
Publication number: 20150073011Abstract: The present invention is directed to compounds which are beta-lacatamase inhibitors. The compounds and their pharmaceutically acceptable salts, are useful in combination with beta-lactam antibiotics, or alone, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to formula (Ia): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3 and R4 are described herein.Type: ApplicationFiled: April 2, 2013Publication date: March 12, 2015Applicant: ASTRAZENECA ABInventors: Helen McGuire, Shanta Bist, Neil Bifulco, Liang Zhao, Ye Wu, Hoan Huynh, Hui Xiong, Janelle Comita-Prevoir, Daemian Dussault, Bolin Geng, Brendan Chen, Thomas Durand-Reville, Satenig Guler
-
Patent number: 8569484Abstract: Compounds of formula (IA) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.Type: GrantFiled: May 28, 2010Date of Patent: October 29, 2013Assignee: Astrazeneca ABInventors: Neil Bifulco, Allison Laura Choy, Olga Quiroga, Brian Alan Sherer
-
Publication number: 20120122817Abstract: Compounds of formula (IA) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.Type: ApplicationFiled: May 28, 2010Publication date: May 17, 2012Applicant: ASTRAZENECA ABInventors: Neil Bifulco, Allison Laura Choy, Olga Quiroga, Brian Alan Sherer
-
Publication number: 20110190280Abstract: The present invention provides thiazole and oxazole compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.Type: ApplicationFiled: August 27, 2008Publication date: August 4, 2011Inventors: George Adjabeng, Neil Bifulco, Ronda G. Davis-Ward, Scott Howard Dickerson, Kelly Horne Donaldson, Philip Anthony Harris, Keith Hornberger, Kimberly Petrov, Tara Renae Rheault, Gregory Schaaf, John Stellwagen, David Edward Uehling, Alex Gregory Waterson
-
Publication number: 20110098296Abstract: The present invention provides thiazole and oxazole compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.Type: ApplicationFiled: December 4, 2008Publication date: April 28, 2011Inventors: George Adjabeng, Neil Bifulco, Ronda G. Davis-Ward, Scott Howard Dickerson, Keith Hornberger, Kimberly Petrov, Tara Renae Rheault, Daivd Edward Uehling, Alex Gregory Waterson
-
Patent number: 7645771Abstract: The present invention relates to compounds of formula (I) or a pharmaceutically acceptable derivatives thereof, useful in the treatment of prophylazis of CCR5-related diseases and disorders, for example, in the inhibition of HIV replication, the prevention or treatment of HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).Type: GrantFiled: December 12, 2003Date of Patent: January 12, 2010Assignee: SmithKline Beecham Corp.Inventors: Wieslaw Mieczyslaw Kazmierski, Chrisopher Joseph Aquino, Neil Bifulco, Eric Eugene Boros, Brian Andrew Chauder, Pek Yoke Chong, Maosheng Duan, Felix Deanda, Jr., Cecilia Suarez Koble, Ed Williams McLean, Jennifer Poole Peckham, Angilique C Perkins, James Benjamin Thompson, Dana Vanderwall
-
Publication number: 20060229336Abstract: The present invention relates to compounds of formula (I) or a pharmaceutically acceptable derivatives thereof, useful in the treatment of prophylazis of CCR5-related diseases and disorders, for example, in the inhibition of HIV replication, the prevention or treatment of HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).Type: ApplicationFiled: December 12, 2003Publication date: October 12, 2006Inventors: Wieslaw Kazmierski, Chrisopher Aquino, Neil Bifulco, Eric Boros, Brian Chauder, Pek Chong, Maosheng Duan, Felix Deanda, Cecilia Koble, Ed Mclean, Jennifer Peckham, Angilique Perkins, James Thompson, Dana Vanderwall
-
Publication number: 20040180891Abstract: This invention relates to pyrazole derivatives of 1Type: ApplicationFiled: March 15, 2004Publication date: September 16, 2004Inventors: Uday Khire, Chengzhi Zhang, Harold C E Kluender, Ingo Mugge, Zhengqui Hong, Jianxing Shao, Neil Bifulco, Pamela A Trail, Jacques Dumas, Rico C Lavoie, Xaio-Gao Liu, Veena Agarwal, Sharad K Verma, Lei Wang
